This post is part of an ongoing series of interviews with investors and entrepreneurs behind some of the most high-profile, invite-only deals on AngelList. In this interview with life sciences VC and early-stage investor Dr. Jenny Rooke, we go inside her investments in Caribou Biosciences... Read more
Some weekend listening for you. Our founder and CEO, Naval Ravikant discusses our recent announcements. Also on iTunes and Soundcloud He covers our 46% unrealized returns, the new Access Fund for retail investors and A-List, our premium recruiting product for busy companies. It's a whopper.... Read more
Today, we're announcing the unrealized return for all 2013 syndicate investments is a 46% IRR and 2.4x multiple. Learn more. These returns are in the upper top quartile of 2013 VC and PE funds, according to Cambridge Associates, the industry standard for measuring VC... Read more
Today we’re announcing A-List, premium recruiting for busy companies. It's ideal for tech companies that want to scale quickly and have the budget to do it. A-List features: Only the best candidates. Humans and algorithms work together to find the top 1% of candidates... Read more
Starting today, all syndicate deals will be private. That means deals will only be shown to investors who have been invited by the syndicate’s lead. Leads won’t be able to share deals with every investor on AngelList anymore, although they can still work... Read more